NeuroScientific Biopharmaceuticals Ltd. has been informed by the Human Research Ethics Committee (HREC) it rejected the Company's planned Phase I Clinical Trial for EmtinBTM. In making its decision, HREC determined that at this stage the supporting documentation did not sufficiently address the risk-benefit profile to justify the conduct of the planned Phase I Clinical Trial. The HREC decision to not approve the Phase I Clinical Trial was unexpected and the Company is seeking clarification on the rationale for the decision to determine what steps can be taken to proceed with the Phase I Clinical Trial.